EUCTR2018-003406-11-ES进行中（未招募）1 期
A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in insulin-naïve subjects with type 2 diabetes mellitus
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 205
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
- •2. Diagnosed with type 2 diabetes mellitus 180 days or longer prior to the day of screening.
- •3. HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory.
- •4. Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):
- •a. Any metformin formulations equal to or above 1500 mg or maximum tolerated or effective dose (as documented in subject’s medical records)
- •b. Free or fixed combination therapy: Metformin as outlined above with or without DPP4i with or without SGLT2i is allowed:
- •b. 1: DPP4i (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose)
- •b.2: SGLT2i (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose )
- •5. Insulin-naïve. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.
- •6. Body mass index (BMI) equal to or above 40.0 kg/m^2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Known or suspected hypersensitivity to trial product(s) or related products.
- •2. Previous participation in this trial. Participation is defined as signed informed consent.
- •3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method.
- •4. Participation in any clinical trial, of an approved or non-approved investigational medicinal product within 90 days before screening.
- •5. Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the investigator’s opinion might jeopardise subject’s safety or compliance with the protocol.
- •6. Any episodes of diabetic ketoacidosis within the past 90 days, prior to the day of screening and between screening and randomisation.
- •7. Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening and between screening and randomisation.
- •8. Presently classified as being in New York Heart Association (NYHA) Class IV.
- •9. Planned coronary, carotid or peripheral artery revascularisation between screening and randomisation.
- •10. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR below 60 ml/min/1.73 m^2 as defined by KDIGO 2012.
- •11. Impaired liver function, defined as Alanine Aminotransferase (ALT) equal to or above 2.5 times or Bilirubin above 1.5 times upper normal limit at screening.
- •12. Inadequately treated blood pressure, defined as Grade 3 hypertension or higher (Systolic equal to or above 180 mmHg or diastolic equal to or above 110 mmHg) at screening.
- •13. Treatment with any medication for the indication of diabetes, or obesity other than stated in the inclusion criteria within the past 90 days, prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.
- •14. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- •15. Presence or history of malignant neoplasms within 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
研究者
相似试验
进行中（未招募）
1 期
A research study to compare two types of insulin: insulin 287 and insulin glargine in people with type 2 diabetes who have not used insulin beforeDiabetes Mellitus, Type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2018-003406-11-PLovo Nordisk A/S200
进行中（未招募）
1 期
A research study in people with type 2 diabetes to compare two types of insulin: insulin 287 and insulin glargineMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2018-003407-18-CZovo Nordisk A/S150
进行中（未招募）
1 期
A research study to compare two types of insulin: insulin 287 and insulin glargine in people with type 2 diabetes who have not used insulin beforeDiabetes Mellitus, Type 2MedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2018-003406-11-HUovo Nordisk A/S200
进行中（未招募）
1 期
A research study to compare two types of insulin: insulin 287 and insulin glargine in people with type 2 diabetes who have not used insulin beforeMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2018-003406-11-SKovo Nordisk A/S200
进行中（未招募）
1 期
A research study to compare two types of insulin: insulin 287 and insulin glargine in people with type 2 diabetes who have not used insulin beforeDiabetes Mellitus, Type 2EUCTR2018-003406-11-DEovo Nordisk A/S200